The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • Events Calendar
    • Current Events
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • AIRR Community Meeting VIII – Decoding and Recoding Immunity
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Programs
    • Conferences
    • Competitions
      • Huston Award
        • Huston Award submission guidelines
      • Research Competition
      • Science Writing
    • Podcast
    • Webinars
  • Business Intelligence
    • Antibody Discovery & Development
      • Antibody Validation
      • Commercializing Antibody Therapeutics
      • Adaptive Immune Receptor Repertoires
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies to Watch
      • Antibodies in early-stage studies
    • Presentations
  • Learning and Career Center
    • Research Resources
      • Antibodies in late-stage clinical studies
    • Education Resources
    • Society Publications
    • Career Shorts
  • Members
    • Login
    • Note to members
    • Member discount codes
  • Sponsors & Partners
You are here: Home / Christine Power, PhD

Christine Power, PhD

Dr. Christine Power graduated from the University of Leeds, UK, with a BSc. Honours degree in Biochemistry, followed by a Ph.D. from the University of Surrey, UK. She has worked in the pharmaceutical and biotech industries in various roles of increasing responsibility in R&D for over 25 years starting at Ciba-Geigy (now Novartis in Switzerland), British Biotechnology Ltd, UK; Glaxo Institute for Molecular Biology (Geneva, Switzerland), Serono and later Merck Serono (part Merck KGaA), Arsanis Biosciences (Vienna, Austria) and most recently for GSK (Stevenage, UK). She has experience working in a variety of therapeutic areas including allergy and asthma, cardiovascular, autoimmune and inflammatory diseases, cancer and infectious diseases. She has broad expertise in the discovery and pre-clinical development of therapeutic proteins and monoclonal antibodies. Whilst working at Serono, Merck Serono and GSK she successfully managed a number of scientific collaborations and funded research projects with pharmaceutical and biotech companies (including start-ups) and academia, and worked with their respective business development units performing due diligence and evaluation of in-licensing opportunities for therapeutic proteins and antibodies as well as for new technologies. Dr. Power has an excellent track record of innovation and productivity in research witnessed by inventorship on over 40 patent applications, and is author of over 80 scientific papers. With this expert background, in 2020, Dr. Power created her own company, Christine Power Consulting based in France, to provide strategic advice and scientific opinion to biotech and pharmaceutical companies, start-ups, and universities in the field of antibody discovery and development.

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals